Skip to main content

Back to the Quill Case: The Unpleasantness of Gray-Area Cases

Image result for rehnquist gold stripes

On April 2, I very briefly discussed the U.S. Supreme Court decision of Vacco v. Quill (1997).  I promised more. So here, at least, is a bit more.

To resume where I left off: the court's opinion, by Chief Justice Rehnquist, said this:

"[W]e disagree with respondents' claim that the distinction between refusing lifesaving medical treatment and assisted suicide is 'arbitrary' and 'irrational.' ... Granted, in some cases, the line between the two may not be clear, but certainty is not required, even were it possible. Logic and contemporary practice support New York's judgment that the two acts are different, and New York may therefore, consistent with the Constitution, treat them differently."

It had by then become customary for some patients to carry the "do not resuscitate" tag with them. The decision to so label a patient was NOT treated as murder. Providing the patient (a mature, rational patient in a lot of pain) with a pill than would enable him to end his own life: THAT was prohibited.  The question is whether this distinction makes sense.

Judging from their comments in oral argument, the Justices in Quill seem to have worried most about slippery slopes. At the bottom of the slope, one can imagine a doctor prescribing a lethal dose of a pill to a teenager who was suffering from the pangs of unrequited love, or dealing with a bad break-up with his/her first love. Imagine this person of majority age but still young enough (and perhaps sheltered enough) to have had little experience of the ups and downs and eventual recovery and new ups in such matters. The strong intuition is that assisting THAT suicide is wrong. Though that hypothetical sounds very different from the actual facts of Quill, the Justices wanted and failed to receive assurances of a firm conceptual distinction somewhere that would serve better than the simple seeming distinction between killing and not-keeping-alive.

What then were the facts in Quill? Dr, Dennis Quill sued New York on behalf of mentally competent terminally ill patients. Crucially, though the pathology was well advanced in the case of each patient involved (and three of them died while the matter was pending before SCOTUS) they were NOT on life sustaining equipment, Thus, there was no "plug" to "pull." That was their equal protection argument: they were being denied the same right to hasten death as would be available to someone who WAS on a respirator or the like, who COULD effectively ask that the plug be pulled.

Personally, I sympathize with the Justices' concern about the slipperiness here. But I have to wonder whether a sort of institutional self-interest plays a part. The Justices don't want to hear a string of heart-breaking cases in various gray areas and to have to make difficult calls. Nor do they want their colleagues in black robes on lower courts to have to do the same. Is that in part simply because it is an agonizing thing to have to do, and they want their own jobs and those of their colleagues to be shielded from that agony?

If it IS their job, then they should be willing to bear it. Nobody should have to, well ... give them a pill to enable them to avoid it!


Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…